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since the use of a prosthetic ring seems to
greatly enhance the durability of the mitral
homograft.2 Using the wall of the aortic
homograft and a low insertion of the valve
so as to exclude the aorto-mitral abscess
when present made unnecessary any recon-
struction of the left atrial roof. The mean
bypass time was 192  11 minutes, which
is comparable with the monobloc aorto-
mitral technique according to Obadia and
suggests that the preservation of an intact
aorto-mitral continuity did not spare any
significant ischemic time. Among our 6 pa-
tients, there was no in-hospital death. One
patient died at 47 months of cerebral hem-
orrhage, and there was one reoperation for
recurrence of endocarditis at 69 months. Af-
ter a mean follow-up of 59 6 months, the
remaining 4 patients were asymptomatic
and 1 patient had had from a normal preg-
nancy. In conclusion, although technically
challenging, a combined aortic and mitral
valve replacement with two separate ho-
mografts can also be a valid option in
highly selected cases.
Christophe Acar, MD
Department of Cardiovascular Surgery
Hôpital Pitié-Salpétrière
Paris, France
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Reply to the Editor:
The comment by Christophe Acar discusses
the alternative between monobloc aorto-
mitral homograft, as my colleagues and I
have proposed, or separate aortic homograft
plus mitral homograft, which he appears to
prefer. In our opinion, the indications are
not strictly the same.1 The patients reported
in Acar’s series were very different from
ours. Our patients had much more severe
disease and always had a history of multi-
ple reoperations with at least one if not two
prostheses in place. The justification for a
monobloc procedure is related to the pres-
ence of a large abscess in the aorto-mitral
curtain, and the main value of monobloc
reconstruction is to allow complete resec-
tion of the aorto-mitral curtain and there-
fore all of the infected tissues. This is im-
possible with a separate aortic replacement
plus mitral replacement, which obviously
leaves all or part of the subaortic curtain in
place.
In contrast with Acar’s claim, the tech-
nique that we propose is not necessarily
more difficult to perform. Access to the
papillary muscle is largely facilitated by a
very large aorto-mitral orifice obtained af-
ter resection of all of the subaortic curtain,
providing excellent exposure of the papil-
lary muscles, which facilitates suture of the
mitral homograft.
Christophe Acar has an extensive experi-
ence with mitral homografts, and his studies
inspired us to systematically insert a mitral
ring onto the mitral homograft to limit, as
rightly suggested by Acar, the risks of mis-
match, which are effectively a risk factor for
secondary homograft dysfunction.
In conclusion, as suggested by Christo-
phe Acar, separate homografts could be
reserved for patients with distinct aortic
and mitral lesions. In contrast, we think it is
logical to maintain the principle of a mono-
bloc procedure, which is the only technique
allowing resection of aorto-mitral abscesses.
I believe that the most important point is
the quality of the resection phase. Ho-
mograft reconstruction has not been dem-
onstrated to be superior to monobloc me-
chanical prosthesis, which can therefore be
preferred in the absence of an available
monobloc homograft in the tissue bank.
Jean-François Obadia, MD, PhD
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What patients want: A new
biological era in valvular prostheses
To the Editor:
We read with great interest the article by
Smedira and associates.1 It deals with the
important issue of valvular disease and
gives further data to help surgeons to
choose the right prosthesis.
One of the points that attracted our at-
tention was the aim of the study. As the
authors clearly expressed, the renewed in-
terest in biologic prostheses reflects in-
creased attention given by patients to the
biologic valve.
We are experiencing a similar trend. An
increasing number of patients are well in-
formed about the benefits and risks of all
types of prostheses when they are admitted
to the hospital for valve replacement. Con-
trary to guidelines, a growing number of
patients prefer to choose a biologic pros-
thesis, even if they are young and will
require a prosthesis replacement. The rea-
sons for this trend vary. First, a patient who
must undergo valve replacement is inter-
ested not only in life expectancy but also in
quality of life. Anticoagulant therapy is
considered a major limitation to quality of
life, especially in those young patients who
have an active lifestyle and do not want to
change their habits. Moreover, they are
more concerned by the risk of thromboem-
bolism linked to mechanical prostheses and
to anticoagulation than by reoperation. Pa-
tients actually know that mortality and
morbidity risks after reoperation are de-
creasing.
Another important topic that is leading
more patients to choose a biologic prosthe-
sis is the strong belief in technology and
technologic advances. Starting with the
consideration that the mean life expect-
ancy of biologic prostheses is calculated
on valves implanted 15 to 20 years ago,
newer prostheses probably will last longer
because they are constructed with new
techniques and treated with new anticalci-
fication treatments. Moreover, those pa-
tients strongly believe that future replace-
ment prostheses probably will have an even
longer life expectancy.
The surgeon must take note of this new
trend. In our institute we are implanting an
increased number of biologic prostheses
even in younger patients. Even the number
of Bentall operations performed with bio-
logic valves is increasing, as is the number
of valve repairs. Moreover, we have started
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a research program with the aim of con-
structing recellularized homografts so that
we can offer new alternatives to mechani-
cal prostheses, as other institutes are doing.
The role of the patient is a determining
factor in the choice of the prosthesis today.
Patients are well informed and their choice
is opening a new era in the field of biologic
prostheses.
Paolo Biglioli, Prof MD
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Is there any difference between
surgical outflow reconstruction and
transcatheter valvotomy in patients
with pulmonary atresia with intact
ventricular septum?
To the Editor:
I read with great interest the article by
Daubeney and associates1 for the UK and
Ireland Collaborative Study of Pulmonary
Atresia with Intact Ventricular Septum.
This is an ongoing population study com-
prising 183 patients. The authors report
that independent risk factors for death were
low birth weight, unipartite right ventricu-
lar morphology, and the presence of a di-
lated ventricle.
The primary procedure comprised a
systemic-pulmonary shunt in 81 patients,
percutaneous transcatheter valvotomy in
40 patients, surgical outflow reconstruction
alone in 27 patients, and surgical outflow
reconstruction with a concomitant shunt in
another 18 patients.
I would like to ask some questions about
patients who received surgical outflow recon-
struction and the group of subjects who un-
derwent a percutaneous approach:
1. Was there any difference in terms of
survival between the two groups?
2. How many subjects treated with
a percutaneous approach needed a
systemic-pulmonary shunt after the
transcatheter procedure?
3. Was there any difference between
the two groups in terms of right
ventricular morphology and/or tri-
cuspid valvular z score?
4. Was there any difference in terms of
the achievement of type of repair
(biventricular, univentricular, mixed,
or one-and-a-half ventricular)?
In fact, there is no agreement about the
best approach to use to open the right ven-
tricular outflow tract in subjects who have
the membranous type of pulmonary atresia
with intact ventricular septum with a tripar-
tite or bipartite right ventricle. Finally, no
comparative studies exist.
Gianfranco Butera, MD, PhD
Department of Pediatric Cardiology
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Reply to the Editor:
In the UK and Ireland Collaborative
Study of Pulmonary Atresia with Intact
Ventricular Septum, 67 of 183 patients
underwent a primary procedure on the
outflow tract without construction of a
shunt: surgical in 27 and transcatheter in
40. Mortality was 26% in the surgical
group and 20% in the catheter group.
Among the survivors, risk of reinterven-
tion within 6 weeks to increase flow of
blood to the lungs was significantly
higher in those who underwent catheter
intervention than in those who underwent
surgery. In many cases this was due to
failure to cross the atretic pulmonary
valve during the initial catheter proce-
dure. When the pulmonary valve was
successfully crossed at catheterization, the
proportion requiring early reintervention was
comparable with that of those treated sur-
gically.
These data represent the earliest expe-
riences in the United Kingdom and Ireland
of catheter perforation and dilatation of the
atretic pulmonary valve in this condition.
In cases in which the atretic pulmonary
valve can successfully be crossed, trans-
catheter intervention can produce good out-
comes in the short term comparable with
those achieved by surgery. Full details will
be published shortly.
Piers Daubeney, MRCPa
Steven Webber, MRCPb
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